These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
201 related articles for article (PubMed ID: 17468644)
21. Prevention of meningococcal disease: current use of polysaccharide and conjugate vaccines. Poland GA Clin Infect Dis; 2010 Mar; 50 Suppl 2():S45-53. PubMed ID: 20144016 [TBL] [Abstract][Full Text] [Related]
22. Economics of an adolescent meningococcal conjugate vaccination catch-up campaign in the United States. Ortega-Sanchez IR; Meltzer MI; Shepard C; Zell E; Messonnier ML; Bilukha O; Zhang X; Stephens DS; Messonnier NE; Clin Infect Dis; 2008 Jan; 46(1):1-13. PubMed ID: 18171206 [TBL] [Abstract][Full Text] [Related]
23. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. Mbaeyi SA; Bozio CH; Duffy J; Rubin LG; Hariri S; Stephens DS; MacNeil JR MMWR Recomm Rep; 2020 Sep; 69(9):1-41. PubMed ID: 33417592 [TBL] [Abstract][Full Text] [Related]
24. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons - Advisory Committee on Immunization Practices, 2016. MacNeil JR; Rubin LG; Patton M; Ortega-Sanchez IR; Martin SW MMWR Morb Mortal Wkly Rep; 2016 Nov; 65(43):1189-1194. PubMed ID: 27811836 [TBL] [Abstract][Full Text] [Related]
25. Recent trends in meningococcal epidemiology and current vaccine recommendations. Baltimore RS Curr Opin Pediatr; 2006 Feb; 18(1):58-63. PubMed ID: 16470164 [TBL] [Abstract][Full Text] [Related]
26. Vaccination coverage among adolescents aged 13-17 years - United States, 2007. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2008 Oct; 57(40):1100-3. PubMed ID: 18846032 [TBL] [Abstract][Full Text] [Related]
27. Statement on conjugate meningococcal vaccine for serogroups A, C, Y and W135. An Advisory Committee Statement (ACS). National Advisory Committee on Immunization (NACI) Can Commun Dis Rep; 2007 May; 33(ACS-3):1-23. PubMed ID: 17520774 [No Abstract] [Full Text] [Related]
28. Recommendation of the Advisory Committee on Immunization Practices (ACIP) for use of quadrivalent meningococcal conjugate vaccine (MenACWY-D) among children aged 9 through 23 months at increased risk for invasive meningococcal disease. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2011 Oct; 60(40):1391-2. PubMed ID: 21993344 [TBL] [Abstract][Full Text] [Related]
35. National vaccination coverage among adolescents aged 13-17 years--United States, 2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2007 Aug; 56(34):885-8. PubMed ID: 17728694 [TBL] [Abstract][Full Text] [Related]
36. Recommended childhood and adolescent immunization schedule. United States, 2003. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2003 Jan; 52(4):Q1-4. PubMed ID: 12578326 [TBL] [Abstract][Full Text] [Related]
37. Recommended childhood immunization schedule--United States, 2002. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2002 Jan; 51(2):31-3. PubMed ID: 11820528 [TBL] [Abstract][Full Text] [Related]
38. Immunogenicity of a single dose of tetravalent meningococcal serogroups A, C, W-135, and Y conjugate vaccine administered to 2- to 10-year-olds is noninferior to a licensed-ACWY polysaccharide vaccine with an acceptable safety profile. Memish ZA; Dbaibo G; Montellano M; Verghese VP; Jain H; Dubey AP; Bianco V; Van der Wielen M; Gatchalian S; Miller JM Pediatr Infect Dis J; 2011 Apr; 30(4):e56-62. PubMed ID: 21278617 [TBL] [Abstract][Full Text] [Related]
39. Timing of adolescent meningococcal conjugate vaccination attitudes and practices of pediatricians and family medicine physicians. Allison MA; Cohn AC; Stokley S; Crane LA; O'Leary ST; Hurley LP; Babbel CI; Dong F; Gahm C; Temte JL; Kempe A Am J Prev Med; 2011 Dec; 41(6):581-7. PubMed ID: 22099234 [TBL] [Abstract][Full Text] [Related]